Allogene Therapeutics Inc (ALLO)

NASDAQ
22.52
+0.91(+4.21%)
  • Volume:
    163,706
  • Bid/Ask:
    22.48/22.54
  • Day's Range:
    21.88 - 22.52

ALLO Overview

Prev. Close
21.61
Day's Range
21.88-22.52
Revenue
38.34M
Open
21.81
52 wk Range
21.1-44.88
EPS
-1.83
Volume
163,706
Market Cap
3.18B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,337,070
P/E Ratio
-
Beta
-
1-Year Change
-44.89%
Shares Outstanding
141,538,421
Next Earnings Date
Aug 11, 2021
What is your sentiment on Allogene Therapeutics Inc?
or
Vote to see community's results!

Allogene Therapeutics Inc News

Allogene Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellSell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong SellStrong Sell

Allogene Therapeutics Inc Company Profile

Allogene Therapeutics Inc Company Profile

Employees
265

Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.

Read More
  • I mean yes
    1
    • no comments! weird! dont you think this is a promising stock?
      0
      • Welcome :)
        0
        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.